Abstract
The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.
| Original language | English |
|---|---|
| Pages (from-to) | 1427-1431 |
| Number of pages | 5 |
| Journal | British Medical Journal |
| Volume | 282 |
| Issue number | 6274 |
| Publication status | Published - 1981 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Multimodal treatment in operable breast cancer : Five-year results of the CMF programme. / Rossi, A.; Bonadonna, G.; Valagussa, P.; Veronesi, U.
In: British Medical Journal, Vol. 282, No. 6274, 1981, p. 1427-1431.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multimodal treatment in operable breast cancer
T2 - Five-year results of the CMF programme
AU - Rossi, A.
AU - Bonadonna, G.
AU - Valagussa, P.
AU - Veronesi, U.
PY - 1981
Y1 - 1981
N2 - The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.
AB - The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44.6%, CMF group 59.5%) and total survival (controls 66.2%, CMF group 78.4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 1.7%, CMF group 1.4%) were not observed. The multimodality approach to treatment of primary breast cancer is a new and important advance. This and other studies are continuing.
UR - http://www.scopus.com/inward/record.url?scp=0019472220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019472220&partnerID=8YFLogxK
M3 - Article
C2 - 6784849
AN - SCOPUS:0019472220
VL - 282
SP - 1427
EP - 1431
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
IS - 6274
ER -